ABVC BioPharma
ABVC
4 hedge funds and large institutions have $1.17M invested in ABVC BioPharma in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.01% less ownership
Funds ownership: 0.16% → 0.15% (-0.01%)
20% less funds holding
Funds holding: 5 → 4 (-1)
25% less capital invested
Capital invested by funds: $1.56M → $1.17M (-$389K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$92K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$17K |
| 3 |
Morgan Stanley
New York
|
-$80 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $1.02M | +$6.34K | +238 | +0.6% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $136K | – | – | – |
|
|
3
Morgan Stanley
New York
| $4K | -$80 | -3 | -2% |
|
|
4
UBS Group
Zurich,
Switzerland
| $3K | -$17K | -639 | -83% |
|
|
VF
5
Virtu Financial
New York
| – | -$92K | -2,722 | Closed |
|
ABVC Hedge Fund Activity: Q1 2022 in Review
4 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q1 2022, worth a combined $1.17M — down 25% from $1.56M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ABVC and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, adding an estimated $6.34K. The largest seller was Virtu Financial, exiting entirely with an estimated $92K sold.
- 4 institutional investors held ABVC BioPharma (ABVC) as of Q1 2022, down from 5 in Q4 2021.
- Funds reported $1.17M of ABVC BioPharma stock for Q1 2022, down 25% quarter-over-quarter.
- 0 funds opened new ABVC BioPharma positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest ABVC BioPharma buyer in Q1 2022 was Vanguard Group, an estimated $6.34K added.
- The largest ABVC BioPharma seller in Q1 2022 was Virtu Financial, an estimated $92K sold.
Based on aggregated 13F filings for Q1 2022.